Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
07
02
2020
accepted:
23
06
2020
revised:
31
05
2020
pubmed:
23
7
2020
medline:
16
3
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
Immunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer (NSCLC) from locally advanced disease to the metastatic setting. This approach has resulted in improved survival and a more favourable toxicity profile when compared with chemotherapy. Following the successful introduction of single-agent immunotherapy, current clinical trials are focusing on combination treatments with chemotherapy or radiotherapy or even other immunotherapeutic agents. However, most of the data available from these trials are derived from, and therefore might be more applicable to younger and fitter patients rather than older and often frail lung cancer real-world patients. This article provides a detailed review of these immunotherapy agents with a focus on the data available regarding older NSCLC patients and makes recommendations to fill evidence gaps in this patient population.
Identifiants
pubmed: 32694695
doi: 10.1038/s41416-020-0986-4
pii: 10.1038/s41416-020-0986-4
pmc: PMC7492214
doi:
Substances chimiques
Antineoplastic Agents
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
874-884Subventions
Organisme : NIA NIH HHS
ID : K76 AG064431
Pays : United States
Organisme : NIA NIH HHS
ID : R03 AG056439
Pays : United States
Références
SEER. Cancer statistics factsheets: lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html (2019).
Sawhney, R., Sehl, M. & Naeim, A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 11, 449–460 (2005).
pubmed: 16393479
doi: 10.1097/00130404-200511000-00004
Sehl, M., Sawhney, R. & Naeim, A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J. 11, 461–473 (2005).
pubmed: 16393480
doi: 10.1097/00130404-200511000-00005
Williams, G. R., Mackenzie, A., Magnuson, A., Olin, R., Chapman, A., Mohile, S. et al. Comorbidity in older adults with cancer. J. Geriatr. Oncol. 7, 249–257 (2016).
pubmed: 26725537
doi: 10.1016/j.jgo.2015.12.002
Tam-McDevitt, J. Polypharmacy, aging, and cancer. Oncology 22, 1052–1055 (2008).
pubmed: 18777955
Yellen, S. B., Cella, D. F. & Leslie, W. T. Age and clinical decision making in oncology patients. J. Natl Cancer Institute 86, 1766–1770 (1994).
doi: 10.1093/jnci/86.23.1766
Hurria, A., Dale, W., Mooney, M., Rowland, J. H., Ballman, K. V., Cohen, H. J. et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J. Clin. Oncol. 32, 2587–2594 (2014).
pubmed: 25071116
pmcid: 4129504
doi: 10.1200/JCO.2013.55.0418
Devons, C. A. Comprehensive geriatric assessment: making the most of the aging years. Curr. Opin. Clin. Nutr. Metab. Care 5, 19–24 (2002).
pubmed: 11790944
doi: 10.1097/00075197-200201000-00004
Extermann, M., Aapro, M., Bernabei, R., Cohen, H. J., Droz, J. P., Lichtman, S. et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit. Rev. Oncol. Hematol. 55, 241–252 (2005).
pubmed: 16084735
doi: 10.1016/j.critrevonc.2005.06.003
Mohile, S. G., Dale, W., Somerfield, M. R., Schonberg, M. A., Boyd, C. M., Burhenn, P. S. et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J. Clin. Oncol. 36, 2326–2347 (2018).
pubmed: 29782209
pmcid: 6063790
doi: 10.1200/JCO.2018.78.8687
Antonio, M., Saldana, J., Linares, J., Ruffinelli, J. C., Palmero, R., Navarro, A. et al. Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer. Br. J. Cancer 118, 639–647 (2018).
pubmed: 29381689
pmcid: 5846066
doi: 10.1038/bjc.2017.455
Maione, P., Perrone, F., Gallo, C., Manzione, L., Piantedosi, F., Barbera, S. et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J. Clin. Oncol. 23, 6865–6872 (2005).
pubmed: 16192578
doi: 10.1200/JCO.2005.02.527
Extermann, M., Boler, I., Reich, R. R., Lyman, G. H., Brown, R. H., DeFelice, J. et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118, 3377–3386 (2012).
pubmed: 22072065
doi: 10.1002/cncr.26646
Hurria, A., Togawa, K., Mohile, S. G., Owusu, C., Klepin, H. D., Gross, C. P. et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J. Clin. Oncol. 29, 3457–3465 (2011).
pubmed: 21810685
pmcid: 3624700
doi: 10.1200/JCO.2011.34.7625
Decoster, L., Van Puyvelde, K., Mohile, S., Wedding, U., Basso, U., Colloca, G. et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. Ann. Oncol. 26, 288–300 (2015).
pubmed: 24936581
doi: 10.1093/annonc/mdu210
Fruh, M., Rolland, E., Pignon, J. P., Seymour, L., Ding, K., Tribodet, H. et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J. Clin. Oncol. 26, 3573–3581 (2008).
pubmed: 18640938
doi: 10.1200/JCO.2008.16.2727
Pepe, C., Hasan, B., Winton, T. L., Seymour, L., Graham, B., Livingston, R. B. et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J. Clin. Oncol. 25, 1553–1561 (2007).
pubmed: 17442999
doi: 10.1200/JCO.2006.09.5570
Battisti, N. M. L., Sehovic, M. & Extermann, M. Assessment of the external validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for non-small-cell lung cancer in a population of patients aged 80 years and older. Clin. Lung Cancer 18, 460–471 (2017).
pubmed: 28416124
doi: 10.1016/j.cllc.2017.03.005
Abe, T., Takeda, K., Ohe, Y., Kudoh, S., Ichinose, Y., Okamoto, H. et al. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. J. Clin. Oncol. 33, 575–581 (2015).
pubmed: 25584004
doi: 10.1200/JCO.2014.55.8627
Gridelli, C., Perrone, F., Gallo, C., Cigolari, S., Rossi, A., Piantedosi, F. et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J. Natl Cancer Institute 95, 362–372 (2003).
doi: 10.1093/jnci/95.5.362
Quoix, E., Zalcman, G., Oster, J. P., Westeel, V., Pichon, E., Lavole, A. et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378, 1079–1088 (2011).
pubmed: 21831418
doi: 10.1016/S0140-6736(11)60780-0
The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J. Natl Cancer Institute 91, 66–72 (1999)
Kudoh, S., Takeda, K., Nakagawa, K., Takada, M., Katakami, N., Matsui, K. et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J. Clin. Oncol. 24, 3657–3663 (2006).
pubmed: 16877734
doi: 10.1200/JCO.2006.06.1044
Hanna, N., Johnson, D., Temin, S., Baker, S. Jr., Brahmer, J., Ellis, P. M. et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 35, 3484–3515 (2017).
pubmed: 28806116
doi: 10.1200/JCO.2017.74.6065
Gridelli, C., Morabito, A., Cavanna, L., Luciani, A., Maione, P., Bonanno, L. et al. Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: joint analysis of MILES-3 and MILES-4 phase III trials. J. Clin. Oncol. 36, 2585–2592 (2018).
pubmed: 30028656
doi: 10.1200/JCO.2017.76.8390
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).
pubmed: 28102259
doi: 10.1038/nature21349
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Cavnar, S., Valencia, P., Brock, J., Wallenstein, J. & Panier, V. The immuno-oncology race: myths and emerging realities. Nat. Rev. Drug Discov. 16, 83–84 (2017).
pubmed: 28148948
doi: 10.1038/nrd.2016.279
Tang, J., Shalabi, A. & Hubbard-Lucey, V. M. Comprehensive analysis of the clinical immuno-oncology landscape. Ann. Oncol. 29, 84–91 (2018).
pubmed: 29228097
doi: 10.1093/annonc/mdx755
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26, 2375–2391 (2015).
pubmed: 26371282
pmcid: 6267867
doi: 10.1093/annonc/mdv383
Kirkwood, T. B. & Austad, S. N. Why do we age? Nature. 408, 233–238 (2000).
pubmed: 11089980
doi: 10.1038/35041682
Nikolich-Zugich, J. The twilight of immunity: emerging concepts in aging of the immune system. Nat. Immunol. 19, 10–19 (2018).
pubmed: 29242543
doi: 10.1038/s41590-017-0006-x
Molony, R. D., Malawista, A. & Montgomery, R. R. Reduced dynamic range of antiviral innate immune responses in aging. Exp. Gerontol. 107, 130–135 (2018).
pubmed: 28822811
doi: 10.1016/j.exger.2017.08.019
Gavazzi, G. & Krause, K. H. Ageing and infection. Lancet Infect. Dis. 2, 659–666 (2002).
pubmed: 12409046
doi: 10.1016/S1473-3099(02)00437-1
Hazeldine, J. & Lord, J. M. Innate immunesenescence: underlying mechanisms and clinical relevance. Biogerontology 16, 187–201 (2015).
pubmed: 25009085
doi: 10.1007/s10522-014-9514-3
Weng, N. P., Akbar, A. N. & Goronzy, J. CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol. 30, 306–312 (2009).
pubmed: 19540809
pmcid: 2801888
doi: 10.1016/j.it.2009.03.013
Wertheimer, A. M., Bennett, M. S., Park, B., Uhrlaub, J. L., Martinez, C., Pulko, V. et al. Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans. J. Immunol. 192, 2143–2155 (2014).
pubmed: 24501199
doi: 10.4049/jimmunol.1301721
Seyda, M., Elkhal, A., Quante, M., Falk, C. S. & Tullius, S. G. T cells going innate. Trends Immunol. 37, 546–556 (2016).
pubmed: 27402226
pmcid: 5633931
doi: 10.1016/j.it.2016.06.004
Manoussakis, M. N., Tzioufas, A. G., Silis, M. P., Pange, P. J., Goudevenos, J. & Moutsopoulos, H. M. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin. Exp. Immunol. 69, 557–565 (1987).
pubmed: 3499270
pmcid: 1542366
Verschoor, C. P., Johnstone, J., Millar, J., Dorrington, M. G., Habibagahi, M., Lelic, A. et al. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J. Leuk. Biol. 93, 633–637 (2013).
doi: 10.1189/jlb.0912461
Lages, C. S., Suffia, I., Velilla, P. A., Huang, B., Warshaw, G., Hildeman, D. A. et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J. Immunol. 181, 1835–1848 (2008).
pubmed: 18641321
doi: 10.4049/jimmunol.181.3.1835
De Martinis, M., Franceschi, C., Monti, D. & Ginaldi, L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 579, 2035–2039 (2005).
pubmed: 15811314
doi: 10.1016/j.febslet.2005.02.055
Johnson, D. E., O’Keefe, R. A. & Grandis, J. R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234–248 (2018).
pubmed: 29405201
pmcid: 5858971
doi: 10.1038/nrclinonc.2018.8
Routy, B., Gopalakrishnan, V., Daillere, R., Zitvogel, L., Wargo, J. A. & Kroemer, G. The gut microbiota influences anticancer immunosurveillance and general health. Nat. Rev. Clin. Oncol. 15, 382–396 (2018).
pubmed: 29636538
doi: 10.1038/s41571-018-0006-2
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A. et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion Score of 50% or Greater. J. Clin. Oncol. 37, 537–546 (2019).
pubmed: 30620668
doi: 10.1200/JCO.18.00149
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A. et al. KEYNOTE-024 3-year survival update: pembrolizumab vs platinum-based chemotherapy for advanced non-small-cell lung cancer. J. Thorac. Oncol. 14, S243 (2019).
doi: 10.1016/j.jtho.2019.08.483
Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819–1830 (2019).
pubmed: 30955977
doi: 10.1016/S0140-6736(18)32409-7
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 387, 1540–1550 (2016).
pubmed: 26712084
doi: 10.1016/S0140-6736(15)01281-7
Nosaki, K., Hosomi, Y., Saka, H., Baas, P., de Castro, G., Jr., Reck, M. et al. Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: pooled analysis from KEYNOTE-010, −024, and −042. Ann. Oncol. 30(Suppl_2), ii48–48 (2019).
doi: 10.1093/annonc/mdz063.001
Nosaki, K., Saka, H., Hosomi, Y., Baas, P., de Castro, G. Jr., Reck, M. et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 135, 188–195 (2019).
pubmed: 31446994
doi: 10.1016/j.lungcan.2019.07.004
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E. et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
pubmed: 26028407
pmcid: 4681400
doi: 10.1056/NEJMoa1504627
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E. et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
pubmed: 26412456
pmcid: 5705936
doi: 10.1056/NEJMoa1507643
Vokes, E. E., Ready, N., Felip, E., Horn, L., Burgio, M. A., Antonia, S. J. et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann. Oncol. 29, 959–965 (2018).
pubmed: 29408986
doi: 10.1093/annonc/mdy041
Horn, L., Spigel, D. R., Vokes, E. E., Holgado, E., Ready, N., Steins, M. et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 35, 3924–3933 (2017).
pubmed: 29023213
pmcid: 6075826
doi: 10.1200/JCO.2017.74.3062
Gettinger, S., Borghaei, H., Brahmer, J., Chow, L., Burgio, M., De Castro Carpeno, J. et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. J. Thorac. Oncol. 14, S244–S245 (2019).
doi: 10.1016/j.jtho.2019.08.486
Antonia, S. J., Borghaei, H., Ramalingam, S. S., Horn, L., De Castro Carpeño, J., Pluzanski, A. et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 20, 1395–1408 (2019).
pubmed: 31422028
pmcid: 7193685
doi: 10.1016/S1470-2045(19)30407-3
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M. et al. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).
pubmed: 28636851
pmcid: 6487310
doi: 10.1056/NEJMoa1613493
Popat, S., Ardizzoni, A., Ciuleanu, T., Cobo Dols, M., Laktionov, K., Szilasi, M. et al. Nivolumab in previously treated patients with metastatic squamous NSCLC: results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status. Ann. Oncol. 28(suppl_5), 463–463 (2017).
doi: 10.1093/annonc/mdx380.006
Spigel, D., Schwartzberg, L., Waterhouse, D., Chandler, J., Hussein, M., Jotte, R. et al. Is nivolumab safe and effective in elderly and PS2 patients with non-small cell lung cancer (NSCLC)? Results of CheckMate 153: Topic: IT. J. Thorac. Oncol. 12, S1287–S1288 (2017).
doi: 10.1016/j.jtho.2016.11.1821
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265 (2017).
doi: 10.1016/S0140-6736(16)32517-X
pubmed: 27979383
Bordoni, R., Ciardiello, F., von Pawel, J., Cortinovis, D., Karagiannis, T., Ballinger, M. et al. Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer. Clin. Lung Cancer 19, 441–449 (2018).
pubmed: 30017645
doi: 10.1016/j.cllc.2018.05.011
CRUK. Cancer statistics in lung cancer. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer (2019).
Rizvi, N. A., Chul Cho, B., Reinmuth, N., Lee, K. H., Ahn, M. J., Luft, A. et al. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. Ann. Oncol. 29(suppl_10), X40–41 (2018).
doi: 10.1093/annonc/mdy511.005
Cho, B. C., Reinmuth, N., Lee, K. H., Ahn, M. J., Luft, A., den Heuvel, M. V. et al. Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC. Ann. Oncol. 30(Supplement_2), ii79–80 (2019).
doi: 10.1093/annonc/mdz094.002
Bracci, L., Schiavoni, G., Sistigu, A. & Belardelli, F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21, 15–25 (2014).
pubmed: 23787994
doi: 10.1038/cdd.2013.67
Wang, Z., Till, B. & Gao, Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology 6, e1331807 (2017).
pubmed: 28811975
pmcid: 5543863
doi: 10.1080/2162402X.2017.1331807
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60–65 (2017).
pubmed: 28397821
pmcid: 5554367
doi: 10.1038/nature22079
Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).
pubmed: 29658856
doi: 10.1056/NEJMoa1801005
Gadgeel, S. M., Garassino, M. C., Esteban, E., Speranza, G., Felip, E., Hochmair, M. J. et al. KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. J. Clin. Oncol. 37(15_suppl), 9013 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.9013
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17, 1497–1508 (2016).
pubmed: 27745820
pmcid: 6886237
doi: 10.1016/S1470-2045(16)30498-3
Borghaei, H., Langer, C. J., Gadgeel, S., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F. et al. 24-month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer. J. Thorac. Oncol. 14, 124–129 (2019).
pubmed: 30138764
doi: 10.1016/j.jtho.2018.08.004
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gumus, M., Mazieres, J. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).
pubmed: 30280635
doi: 10.1056/NEJMoa1810865
Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J. et al. Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407. Ann. Oncol. 30(Suppl_5), V918–919 (2019).
doi: 10.1093/annonc/mdz394.080
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018).
doi: 10.1056/NEJMoa1716948
pubmed: 29863955
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924–937 (2019).
pubmed: 31122901
doi: 10.1016/S1470-2045(19)30167-6
Barlesi, F., Nishio, M., Cobo, M., Steele, N., Paramonov, V., Parente, B. et al. IMpower132: efficacy of atezolizumab + carboplatin/cisplatin + pemetrexed as 1L treatment in key subgroups with stage IV non-squamous NSCLC. Ann. Oncol. 29(S8), VIII743–744 (2018).
doi: 10.1093/annonc/mdy424.066
Jotte, R. M., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Abreu, D. R., Hussein, M. A. et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J. Clin. Oncol. 36(S18), LBA9000 (2018).
doi: 10.1200/JCO.2018.36.18_suppl.LBA9000
Jotte, R., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Abreu, D. R., Hussein, M. et al. IMpower131: final OS results of carboplatin + nab-paclitaxel +/- atezolizumab in advanced squamous NSCLC. J. Thorac. Oncol. 14, S243–S244 (2019).
doi: 10.1016/j.jtho.2019.08.484
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).
pubmed: 29658845
pmcid: 7193684
doi: 10.1056/NEJMoa1801946
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S. W., Carcereny Costa, E. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019).
pubmed: 31562796
doi: 10.1056/NEJMoa1910231
Paz-Ares, L., Urban, L., Audigier-Valette, C., Grossi, F., Jao, K., Aucoin, J. et al. CheckMate 817: safety of flat-dose nivolumab plus weight-based ipilimumab for the first-line (1L) treatment of advanced NSCLC. J. Thorac. Oncol. 13, S493 (2018).
doi: 10.1016/j.jtho.2018.08.635
Barlesi, F., Audigier-Valette, C., Felip, E., Ciuleanu, T., Jao, K., Rijavec, E. et al. CheckMate 817: first-line nivolumab + ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC. J. Thorac. Oncol. 14, S214–S215 (2019).
doi: 10.1016/j.jtho.2019.08.424
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58, 862–870 (2004).
pubmed: 14967443
doi: 10.1016/j.ijrobp.2003.09.012
Wang, X., Schoenhals, J. E., Li, A., Valdecanas, D. R., Ye, H., Zang, F. et al. Suppression of Type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 77, 839–850 (2017).
doi: 10.1158/0008-5472.CAN-15-3142
pubmed: 27821490
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458 (2014).
pubmed: 25274032
doi: 10.1158/0008-5472.CAN-14-1258
Sato, H., Niimi, A., Yasuhara, T., Permata, T. B. M., Hagiwara, Y., Isono, M. et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat. Commun. 8, 1751 (2017).
pubmed: 29170499
pmcid: 5701012
doi: 10.1038/s41467-017-01883-9
Barker, H. E., Paget, J. T., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409–425 (2015).
pubmed: 26105538
pmcid: 4896389
doi: 10.1038/nrc3958
Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C. et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 18, 895–903 (2017).
pubmed: 28551359
pmcid: 5538772
doi: 10.1016/S1470-2045(17)30380-7
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379, 2342–2350 (2018).
pubmed: 30280658
doi: 10.1056/NEJMoa1809697
Vansteenkiste, J. F., Naidoo, J., Faivre-Finn, C., Özgüroğlu, M., Villegas, A., Daniel, D. et al. Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC). Ann. Oncol. 30(Supp_5), V592–593 (2019).
doi: 10.1093/annonc/mdz259.002
Palma, D. A., Senan, S., Tsujino, K., Barriger, R. B., Rengan, R., Moreno, M. et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol Phys. 85, 444–450 (2013).
pubmed: 22682812
doi: 10.1016/j.ijrobp.2012.04.043
Voong, K. R., Hazell, S. Z., Fu, W., Hu, C., Lin, C. T., Ding, K. et al. Relationship between prior radiotherapy and Checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer. Clin. Lung Cancer 20, e470–e479 (2019).
pubmed: 31031204
doi: 10.1016/j.cllc.2019.02.018
pmcid: 8767572
Mohile, S. G., Dale, W., Somerfield, M. R., Schonberg, M. A., Boyd, C. M., Burhenn, P. S. et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J. Clin. Oncol. 36, 2326–2347 (2018).
pubmed: 29782209
pmcid: 6063790
doi: 10.1200/JCO.2018.78.8687
Gomes, F., Woolley, S., Califano, R., Summers, Y., Baker, K., Burns, K. et al. Elderly lung cancer patients on immunotherapy: preliminary results from the ELDERS study. J. Thorac. Oncol. 12, S1841–S1842 (2017).
doi: 10.1016/j.jtho.2017.09.538
Popat, S., Ardizzoni, A., Ciuleanu, T., Cobo Dols, M., Laktionov, K., Szilasi, M. et al. 1303PDNivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status. Ann. Oncol. 28(suppl_5), V463–463 (2017).
doi: 10.1093/annonc/mdx380.006
Spigel, D., Schwartzberg, L., Waterhouse, D., Chandler, J., Hussein, M., Jotte, R. et al. P3.02c-026 is nivolumab safe and effective in elderly and PS2 patients with non-small cell lung cancer (NSCLC)? Results of CheckMate 153: Topic: IT. J. Thorac. Oncol. 12, S1287–S1288 (2017).
doi: 10.1016/j.jtho.2016.11.1821
Middleton, G., Brock, K., Summers, Y., Connibear, J., Shah, R., Ottensmeier, C. et al. Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): results of the PePS2 trial. Ann. Oncol. 29(suppl_8), VIII497–497 (2018).
doi: 10.1093/annonc/mdy292.007
Grossi, F., Crino, L., Logroscino, A., Canova, S., Delmonte, A., Melotti, B. et al. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. Euro. J. Cancer 100, 126–134 (2018).
doi: 10.1016/j.ejca.2018.05.015
Migliorino, M. R., Gelibter, A., Grossi, F., Fagnani, D., Bordi, P., Franchina, T. et al. Use of nivolumab in elderly patients with advanced non-squamous NSCLC: results from the Italian expanded access program (EAP). Ann. Oncol. 28(suppl_5), V471–471 (2017).
doi: 10.1093/annonc/mdx380.023
Grossi, F., Genova, C., Crinò, L., Delmonte, A., Turci, D., Signorelli, D. et al. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer. Euro. J. Cancer 123, 72–80 (2019).
doi: 10.1016/j.ejca.2019.09.011
Luciani, A., Toschi, L., Fava, S., Cortinovis, D., Filipazzi, V., Tuzi, A. et al. 1472PImmunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): a multicenter Italian experience. Ann. Oncol. 29(suppl_8), VIII533–533 (2018).
doi: 10.1093/annonc/mdy292.094
Haanen, J., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28(suppl_4), iv119–iv142 (2017).
doi: 10.1093/annonc/mdx225
pubmed: 28881921
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl 4), iv192–iv237 (2018).
pubmed: 30285222
doi: 10.1093/annonc/mdy275
Gajra, A., Zemla, T. J., Jatoi, A., Feliciano, J. L., Wong, M. L., Chen, H. et al. Time-to-treatment-failure and related outcomes among 1000+ advanced non-small cell lung cancer patients: comparisons between older versus younger patients (Alliance A151711). J. Thorac. Oncol. 13, 996–1003 (2018).
pubmed: 29608967
pmcid: 6015776
doi: 10.1016/j.jtho.2018.03.020
Wildiers, H., Mauer, M., Pallis, A., Hurria, A., Mohile, S. G., Luciani, A. et al. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer–Alliance for Clinical Trials in Oncology–International Society Of Geriatric Oncology position article. J. Clin. Oncol. 31, 3711–3718 (2013).
pubmed: 24019549
doi: 10.1200/JCO.2013.49.6125